Downloads: 0 | Views: 143

Research Paper | Health Sciences | Iraq | Volume 12 Issue 12, December 2023 | Popularity: 4.8 / 10

Rate This Article!      

The Potential Survival Advantages of Rivaroxaban in Patients with COVID-19 and its Relationship with D-Dimer Levels at the Time of Early Onset of Anticoagulation

Dhiaa Lattef Gossa Al-Saadde, Oday Sajjad Alsawad

Abstract: The current work aimed to assess the rate of death, hospitalization, and oxygen supplementation, in addition to assessing major or clinically relevant non-major bleeding. Methods: In a prospective cohort study involving 392 outpatients diagnosed with COVID-19, all patients were followed up for one month, and the patients received Rivaroxaban 20 mg once daily. The investigators took out patients' information regarding their sociodemographic data, past medical history, laboratory investigation (complete blood picture, D-Dimer, renal and liver functions tests), side effects of drugs, and clinical outcomes. Results: Most of the cases had moderate COVID-19, and the rest had severe COVID-19; regarding death, only 2% died, 3.6% were hospitalized during the follow-up period, and 2.3% received oxygen supplementation. Total bleeding as a complication accounted for 17.3%, 0.5% had major bleeding, and 16.8% had clinically irrelevant bleeding. There was no association between COVID severity, D-dimer levels, death and hospitalization, and total bleeding. Conclusion: Rivaroxaban 20 mg once daily as a prophylactic option for COVID-19 with moderate to severe appears to be safe and effective.

Keywords: COVID-19, Rivaroxaban, bleeding, anticoagulation, death

Edition: Volume 12 Issue 12, December 2023

Pages: 1260 - 1265

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article

Similar Articles